Background: Patients with colorectal cancer are often excluded from clinical trials based on age or a poor performance score. However, 70% of colorectal cancer is diagnosed in patients over 65. Evaluation on the influence of age and comorbidity on survival and cause of death in a non-selected population.
Methods: Included were 621 consecutive patients with colorectal cancer. An extensive chart review was performed for 392 patients with colon cancer and 143 patients with rectal cancer. Analyses were performed separately for both groups.
Results: Median survival of colon cancer patients was 5.13 years, 131 patients (34.3%) died from tumour progression. Age and comorbidity were significant predictors for overall survival (P<0.001). Age was also a significant predictor of cause of death (P=0.001). In rectal cancer patients median survival was 4.67 years, 51 (35.7%) of patients died from tumour progression. Neither age nor comorbidity was significant predictors of survival. Age was a significant predictor of cause of death (P<0.001).
Conclusions: In colon cancer patient age and comorbidity predict survival. This represents possible bias or a reduced survival benefit of treatment, and is an indication that colon cancer is not the prognosis defining illness in the majority of patients. In rectal cancer patients neither age or comorbidity significantly impacted survival.
Keywords: Charlson score; Colorectal cancer; co-morbidity; epidemiology; survival.
Conflict of interest statement
Aspects of survival from colorectal cancer in Denmark.Dan Med J. 2012 Apr;59(4):B4428. Dan Med J. 2012. PMID: 22459726
Comorbidity and survival of Danish patients with colon and rectal cancer from 2000-2011: a population-based cohort study.Clin Epidemiol. 2013 Nov 1;5(Suppl 1):65-74. doi: 10.2147/CLEP.S47154. eCollection 2013. Clin Epidemiol. 2013. PMID: 24227924 Free PMC article.
Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.Eur J Cancer. 2017 Aug;81:90-101. doi: 10.1016/j.ejca.2017.05.024. Epub 2017 Jun 13. Eur J Cancer. 2017. PMID: 28622612 Clinical Trial.
[The efficacy of the multidisciplinary approach in colorectal cancer surgery in elderly patients].Khirurgiia (Mosk). 2012;(2):4-13. Khirurgiia (Mosk). 2012. PMID: 22678468 Review. Russian.
Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.Cochrane Database Syst Rev. 2004;(2):CD000279. doi: 10.1002/14651858.CD000279.pub2. Cochrane Database Syst Rev. 2004. PMID: 15106148 Updated. Review.
Cited by 17 articles
Survival Status and Predictors of Mortality Among Colorectal Cancer Patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Retrospective Followup Study.J Cancer Prev. 2020 Mar 30;25(1):38-47. doi: 10.15430/JCP.2020.25.1.38. J Cancer Prev. 2020. PMID: 32266178 Free PMC article.
Mixture cure model for estimating short-term and long-term colorectal cancer survival.Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S37-S43. Gastroenterol Hepatol Bed Bench. 2019. PMID: 32099600 Free PMC article.
Prognostic analysis of very early onset pancreatic cancer: a population-based analysis.PeerJ. 2020 Feb 10;8:e8412. doi: 10.7717/peerj.8412. eCollection 2020. PeerJ. 2020. PMID: 32095324 Free PMC article.
Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients.Langenbecks Arch Surg. 2020 Feb;405(1):71-80. doi: 10.1007/s00423-019-01850-6. Epub 2020 Jan 31. Langenbecks Arch Surg. 2020. PMID: 32002628 Free PMC article.
CancerClock: A DNA Methylation Age Predictor to Identify and Characterize Aging Clock in Pan-Cancer.Front Bioeng Biotechnol. 2019 Dec 4;7:388. doi: 10.3389/fbioe.2019.00388. eCollection 2019. Front Bioeng Biotechnol. 2019. PMID: 31867319 Free PMC article.